Carl Zeiss Meditec AG
- WKN: 531370
- ISIN: DE0005313704
- Land: Deutschland
Nachricht vom 06.08.2021 | 07:00
Carl Zeiss Meditec records significant increase in revenue and raises annual targets
DGAP-News: Carl Zeiss Meditec AG
/ Key word(s): 9 Month figures/Quarterly / Interim Statement
JENA, 6 August 2021
Carl Zeiss Meditec generated revenue of €1,198.2m in the first nine months of fiscal year 2020/21 (prior year: €967.9m), growing by +23.8% (adjusted for currency effects: +27.6%). Earnings before interest and taxes (EBIT) increased overproportionally, to €282.8m (prior year: €111.9m). The EBIT margin was 23.6% (prior year: 11.6%).
Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG: "Our business is making an increasingly perceptible recovery from the effects of the COVID-19 pandemic. In addition to the renewed strong growth in recurring revenue, we also achieved further progress in our equipment business."
All strategic business units contribute to growth
Revenue in the strategic business unit (SBU) Ophthalmic Devices increased by +30.2% in the first nine months of fiscal year 2020/21 (adjusted for currency effects: +33.9%), to €923.4m (prior year: €709.1m). In particular, the business with recurring revenue from consumables, implants and services made a significant contribution to this growth. The recovery of revenue continued in the strategic business unit Microsurgery; there was an acceleration in the third quarter in particular. Revenue increased by +6.2% in the first nine months (adjusted for currency effects: +10.4%), to €274.8m (prior year: €258.7m).
High growth rates in all reporting regions
Revenue in the EMEA region increased by +18.0% (adjusted for currency effects: +19.8%), to €317.3m (prior year: €268.8m). Once again, there was a positive trend in the markets of Germany, France and Southern Europe, and the UK.
Revenue in the Americas region increased by a further +12.3%, to €305.9m, due to the further acceleration in the US business (prior year: €272.3m) - adjusted for currency effects, revenue increased by +21.0%.
Once again, the APAC region made the strongest contribution to growth. Revenue increased by 34.7% (adjusted for currency effects: +36.7%) to €575.0m (prior year: €426.8m). China and South Korea had the highest growth rates.
Significant increase in operating result year-on-year
The operating result (earnings before interest and taxes: EBIT) increased disproportionately in the first nine months of fiscal year 2020/21, to €282.8m (prior year: €111.9m). This was driven in particular by a favorable product mix and a high proportion of recurring revenue, as well as low selling and marketing expenses. The EBIT margin increased to 23.6% (prior year: 11.6%). Adjusted for special effects, this resulted in an increase to 23.9% (prior year: 12.1%). Earnings per share increased to €2.04 (prior year: €0.77).
Due to the positive development of business, the Company has raised its targets for the current fiscal year 2020/21. Revenue is expected to exceed the previous target of around €1.6bn (prior year: €1,335.5bn). The EBIT margin is expected to significantly exceed the previous target of around 20% in fiscal year 2020/21 (prior year: 13.3%), bolstered to a great extent by the current low selling and marketing expenses.
Revenue by region
Further information on our publication and the Analyst Conference Call on the results for the first nine months of fiscal year 2020/21 can be found at
Contact for investors and press
|Company:||Carl Zeiss Meditec AG|
|Göschwitzer Str. 51-52|
|07745 Jena, Germany|
|Phone:||+49 (0)3641 220-0|
|Fax:||+49 (0)3641 220-112|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1224462|
|End of News||DGAP News Service|
Change to Executive Board of Carl Zeiss Meditec AG
Leadership Change in the Executive Board of Ca ...
Carl Zeiss Meditec AG: Release according to Ar ...
Carl Zeiss Meditec records significant increas ...
Carl Zeiss Meditec AG: Preliminary announcemen ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
26. November 15:53 Devisen: Droht wegen Lira-Crash eine Banken-Krise?
26. November 15:59 Performance mit Megatrendaktien
26. November 16:00 Gigantisch: 100 Millionen Roboter für Nvidia und Meta sorgen für ...
26. November 16:04 Zoom: Richtungswechsel, aber Chartbild bleibt eindeutig
26. November 16:15 Sartorius: 70 Prozent Trading-Chance bei diesem Corona-Profiteur
News im Fokus
Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon
25. November 2021, 17:45
Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten
26. November 2021